IGC PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
IGC PHARMA, INC. (IGC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 208.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-14
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 209.00%.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 171.00%, a 2.29% decline year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-06-30 was 175.00%, a 38.60% decline year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-06-30 was 285.00%, a 0.00% change year-over-year.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 171.00%, a 2.29% decline from fiscal 2024.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 175.00%, a 37.94% decline from fiscal 2023.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 282.00%, a 0.00% change from fiscal 2022.
- IGC PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 282.00%, a 13.25% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 208.00% 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | 209.00% 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | 211.00% 10-KT · filed 2026-03-18 | 175.00% 10-Q · filed 2026-08-14 | |||
| 2025-09-30 | 144.00% 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | 171.00% 10-Q · filed 2025-08-14 | ||||
| 2025-03-31 | 171.00% 10-KT · filed 2026-03-18 | ||||
| 2024-12-31 | 174.00% 10-Q · filed 2025-02-14 | ||||
| 2024-09-30 | 175.00% 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | 175.00% 10-Q · filed 2024-08-07 | ||||
| 2024-03-31 | 175.00% 10-K · filed 2025-06-27 | ||||
| 2023-12-31 | 262.00% 10-Q · filed 2024-02-14 | ||||
| 2023-09-30 | 280.00% 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | 285.00% 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | 282.00% 10-K · filed 2024-06-24 | 280.00% 10-K · filed 2023-07-07 | |||
| 2022-12-31 | 285.00% 10-Q · filed 2023-02-14 | ||||
| 2022-09-30 | 285.00% 10-Q · filed 2022-11-01 | ||||
| 2022-06-30 | 285.00% 10-Q · filed 2022-08-05 | ||||
| 2022-03-31 | 282.00% 10-K · filed 2023-07-07 | ||||
| 2021-12-31 | 281.00% 10-Q · filed 2022-02-10 | ||||
| 2021-09-30 | 281.00% 10-Q · filed 2021-10-29 | ||||
| 2021-06-30 | 281.00% 10-Q · filed 2021-08-11 | ||||
| 2021-03-31 | 249.00% 10-K · filed 2022-06-23 | ||||
| 2020-12-31 | 249.00% 10-Q · filed 2022-02-10 | ||||
| 2020-09-30 | 249.00% 10-Q · filed 2021-10-29 | ||||
| 2020-06-30 | 249.00% 10-Q · filed 2021-08-11 | ||||
| 2020-03-31 | 249.50% 10-K · filed 2021-06-14 | 249.00% 10-K · filed 2020-07-13 | |||
| 2019-12-31 | 249.00% 10-Q · filed 2021-02-16 | ||||
| 2019-09-30 | 249.00% 10-Q · filed 2020-11-20 | ||||
| 2019-06-30 | 249.00% 10-Q · filed 2020-08-19 | ||||
| 2019-03-31 | 119.50% 10-K · filed 2020-07-13 | ||||
| 2018-12-31 | 119.50% 10-Q · filed 2020-02-10 | ||||
| 2018-09-30 | 119.50% 10-Q · filed 2019-11-06 | ||||
| 2018-06-30 | 119.50% 10-Q · filed 2019-08-09 | ||||
| 2018-03-31 | 119.50% 10-K · filed 2019-06-14 | ||||
| 2017-03-31 | 119.50% 10-K · filed 2017-07-14 | ||||
| 2014-03-31 | 35.35% 10-K · filed 2014-07-15 | ||||
| 2013-03-31 | 83.37% 10-K · filed 2014-07-15 | ||||
| 2011-06-30 | 83.37% 10-K · filed 2016-07-14 | ||||
| 2010-03-31 | 35.35% 10-K · filed 2015-07-14 | ||||
| 2009-12-31 | 35.35% 10-K · filed 2014-07-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |